0001105806-18-000004.txt : 20180214 0001105806-18-000004.hdr.sgml : 20180214 20180214094024 ACCESSION NUMBER: 0001105806-18-000004 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180214 DATE AS OF CHANGE: 20180214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Recro Pharma, Inc. CENTRAL INDEX KEY: 0001588972 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261523233 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88042 FILM NUMBER: 18607969 BUSINESS ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (484) 395-2400 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LYTTON LAURENCE W CENTRAL INDEX KEY: 0001105806 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 467 CPW CITY: NY STATE: NY ZIP: 10025 SC 13G/A 1 reph.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment 1) Under the Securities Exchange Act of 1934 (Name of Issuer) Recro Pharma, Inc. (Title of Class of Securities) Common Stock (CUSIP Number) 75629F109 (Date of Event Which Requires Filing of this Statement) December 31, 2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]Rule 13d-1(b) [ X ]Rule 13d-1(c) [ ]Rule 13d-1(d) CUSIP No. 75629F109 1.Names of Reporting Persons. Laurence W.Lytton 2. Check the Appropriate Box if a Member of a Group (See Instructions) a).......................................................................... (b).......................................................................... 3.SEC Use Only 4.Citizenship or Place of Organization USA 5.Sole Voting Power 859,281 6.Shared Voting Power 18,700 7.Sole Dispositive Power 859,281 8.Shared Dispositive Power 18,700 9.Aggregate Amount Beneficially Owned by Each Reporting Person 877,981 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)................................. 11.Percent of Class Represented by Amount in Row (9) 4.6% (1) (1) Based on 19,123,935 shares outstanding As of November 7, 2017 as reported in the Sept 30, 2017 10-Q. 12.Type of Reporting Person (See Instructions) IN Item 1. (a)Name of Issuer Recro Pharma, Inc. (b)Address of Issuer's Principal Executive Offices 490 Lapp Road, Malvern, Pennsylvania 19355 Item 2. (a)Name of Person Filing Laurence W. Lytton (b)Address of Principal Business Office or, if none, Residence 467 CPW N.Y., NY 10025 (c)Citizenship USA (d)Title of Class of Securities Common (e)CUSIP Number 75629F109 Item 3. not applicable Item 4.Ownership. (a)Amount beneficially owned: 877,981 consisting of 636,106 shares held by the reporting person, 65,763 held in the AWL Family LLC, 66,759 held in the IKL Trust, 53,162 held in the KLL Family Trust, 32,391 held in the L-K Foundation, and 23,800 shares held in other related accounts. (b)Percent of class: 4.6% (c)Number of shares as to which the person has: (i)Sole power to vote or to direct the vote 859,281 (ii)Shared power to vote or to direct the vote 18,700 (iii)Sole power to dispose or to direct the disposition of 859,281 (iv)Shared power to dispose or to direct the disposition of 18,700 Item 5.Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following (X). Item 6.Ownership of More than Five Percent on Behalf of Another Person. Not applicable Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable Item 8.Identification and Classification of Members of the Group Not applicable Item 9.Notice of Dissolution of Group Not applicable Item 10.Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. ___2/14/18____________________________ Date ____s/ Laurence W. Lytton____________________________ Signature _____Laurence W. Lytton___________________________ Name/Title